PMV Pharma reports FY2021 net loss of $57.8M; cash at $314.1M; PC14586 data expected H1 2022

PMV Pharmaceuticals, Inc.

2022-FY EPS reported -$1.28

Net loss $57.8M in FY2021 vs $34.4M in FY2020; R&D expenses $36.5M; G&A $21.8M.
Cash, cash equivalents and marketable securities $314.1M as of Dec 31, 2021 vs $361.4M Dec 31, 2020; net cash used in operations $46.6M.
Lead candidate PC14586 Phase 1/2 trial ongoing; initial Phase 1 data expected in first half of 2022.
Advanced WIP1 inhibitor program into lead optimization; appointed Kirsten Flowers to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.